New perspectives on biological HDL-targeted therapies

摘要

According to a modified high-density lipoprotein (HDL) hypothesis, improving HDL function will lead to a decrease of coronary events. The stringent requirement for proving or refuting this hypothesis is that the causal pathway between the therapeutic intervention and a clinically meaningful endpoint obligatory passes through HDL. Infusion therapy of reconstituted HDL particles and human apolipoprotein A-I gene transfer are biological HDL-targeted therapies that are distinguished by HDL specificity. In addition, recombinant lecithin:cholesterol acyltransferase therapy is developed since this enzyme might be rate-limiting in patients with coronary heart disease. The potential of biological HDL-targeted therapies is discussed from a clinical perspective.